This excerpt taken from the BEC 10-Q filed May 8, 2007.
On May 1, 2007, the Company entered into a revised merger agreement with Biosite® Incorporated (Biosite), a leading biomedical company commercializing proteomics discoveries for the advancement of medical diagnosis. Under the terms of the revised merger agreement, the Company will acquire all of Biosites outstanding common stock in a cash tender offer for $90.00 per share (an increase of $5.00 per share over the original merger agreement dated March 24, 2007) or approximately $1.67 billion in total on a fully diluted basis. The tender offer for Biosites outstanding common stock is valid until May 15, 2007. The Company has obtained commitment letters for an interim loan facility to finance the acquisition and expects to replace the interim loan facility within 90 days, using permanent financing consisting of approximately $800 million in convertible notes with the balance composed of long-term debt.
The Company is engaged primarily in the design, manufacture and sale of laboratory instrument systems and related products. The Company has one business segment consisting of four business groups focused on driving core product strategies. These business groups are Chemistry Systems, Cellular Systems, Immunoassay Systems, and Discovery and Automation Systems. The Companys CEO, who is also the Companys chief operating decision maker, evaluates the Companys various global product portfolios on a revenue basis, and profitability is evaluated on an enterprise-wide basis due to shared infrastructures.